Aerovate Therapeutics, Inc.
AVTE
$2.66
$0.083.10%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 21.41M | 20.79M | 18.19M | 17.58M | 17.19M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 74.60M | 90.26M | 94.22M | 88.39M | 81.41M |
| Operating Income | -74.60M | -90.26M | -94.22M | -88.39M | -81.41M |
| Income Before Tax | -69.57M | -84.56M | -87.88M | -82.13M | -75.47M |
| Income Tax Expenses | 55.00K | 56.00K | 56.00K | 56.00K | 56.00K |
| Earnings from Continuing Operations | -69.63 | -84.61 | -87.94 | -82.19 | -75.52 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -69.63M | -84.61M | -87.94M | -82.19M | -75.52M |
| EBIT | -74.60M | -90.26M | -94.22M | -88.39M | -81.41M |
| EBITDA | -74.31M | -89.96M | -94.11M | -88.29M | -81.31M |
| EPS Basic | -2.45 | -3.00 | -3.14 | -3.04 | -2.87 |
| Normalized Basic EPS | -1.53 | -1.87 | -1.96 | -1.90 | -1.79 |
| EPS Diluted | -2.45 | -3.00 | -3.14 | -3.04 | -2.87 |
| Normalized Diluted EPS | -1.53 | -1.87 | -1.96 | -1.90 | -1.79 |
| Average Basic Shares Outstanding | 114.03M | 113.11M | 111.89M | 108.30M | 105.28M |
| Average Diluted Shares Outstanding | 114.03M | 113.11M | 111.89M | 108.30M | 105.28M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
